Arrowhead Pharmaceuticals

This early-stage study tested a new drug called ARC-521 in 47 people, including healthy volunteers and patients with chronic hepatitis B. The goal was to check safety and how the body processes the drug. The trial was stopped early, so results are limited.

This study tested an experimental drug called ARC-520, given with a standard antiviral (entecavir), to lower hepatitis B surface antigen levels in people with chronic hepatitis B. The trial included 58 participants and was stopped early. The goal was to control the virus, not cur…

This early-phase study tested a drug called ARC-AAT in healthy volunteers and people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can damage the lungs and liver. The main goal was to check safety and how the drug affects levels of a key protein. The study …

This study tested an experimental drug called ARC-520, given alongside standard hepatitis B medications (entecavir or tenofovir), in people with chronic hepatitis B. The goal was to see if it could lower the amount of hepatitis B surface antigen in the blood. Only 4 people took p…

This study tested an experimental drug called ARC-520 in 79 adults with chronic hepatitis B. Some participants received ARC-520 alone, while others got it with standard treatments like entecavir or tenofovir. The goal was to see if ARC-520 could lower hepatitis B surface antigen …

This study tested a new drug called ARC-520, given with standard antiviral pills, to see if it could lower hepatitis B virus levels in people with chronic infection. The trial included 58 adults who had been on antiviral treatment for at least 2 months. The study was stopped earl…

This study looked at adding an experimental drug called ARC-520 to standard hepatitis B treatments (entecavir or tenofovir) in 12 people with chronic hepatitis B. Participants received 9 doses of ARC-520 over 36 weeks. The goal was to see if the combination could reduce a key vir…

This study tested an inhaled drug called ARO-MUC5AC in healthy people and those with moderate-to-severe asthma or COPD. The goal was to see if it is safe and how the body processes it. The study was stopped early, so results are limited. About 78 people were planned to take part.

This study tested an experimental drug called ARC-520 in 32 adults with chronic hepatitis B who were already taking standard antiviral medications. Participants received either ARC-520 or a placebo added to their usual treatment. The goal was to see if ARC-520 could further reduc…

This study tested an experimental drug called ARO-ENaC in healthy volunteers and people with cystic fibrosis. The goal was to see if it is safe and helps lung function. The study was stopped early, so results are limited.